DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer

Information source: Reproductive Medicine Associates of New Jersey
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Control Media Only; Study hCG and Media

Intervention: hCG at the Time of Embryo Transfer (Other); Control (Other)

Phase: N/A

Status: Completed

Sponsored by: Reproductive Medicine Associates of New Jersey

Official(s) and/or principal investigator(s):
Richard T Scott, MD, Principal Investigator, Affiliation: Reproductive Medicine Associates of New Jersey

Summary

Techniques to improve pregnancy and delivery rates in IVF cycles have focused not only on the embryos transferred, but also the conditions in the uterus at the time of transfer and implantation. Prior studies have shown that embryos secrete human chorionic gonadotropin (hCG) prior to implantation. However, in IVF cycles, the embryos have limited time to secrete hCG before implantation must occur because embryos are placed into the uterus rather than traveling there from the fallopian tubes. Recent studies have shown that the introduction of hCG into the uterus prior to embryo transfer may make the uterus more receptive to implantation. These studies involved day 3 embryos and the investigators are seeking to evaluate the potential benefits of hCG on implantation rates of blastocysts (day 5 or day 6 embryos). The purpose of this study is to determine whether infusion of human chorionic gonadotropin (hCG) into the uterus immediately prior to embryo transfer results in increased implantation rates. The entire IVF cycle, fresh or frozen, will be conducted per routine. All laboratory culture conditions will be per routine. In fresh and frozen IVF cycles, an embryo transfer will be performed per routine. At the time of embryo transfer, participants will be randomly assigned to either the control group or the hCG group. Patients in the hCG group will have a mock embryo transfer with 20µL of transfer media including 500IU of hCG. Patients in the control group will have a mock embryo transfer with 20µL of transfer media. All post-transfer care and pregnancy monitoring will be identical and per routine protocol.

Clinical Details

Official title: Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer: A Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Sustained implantation rate

Secondary outcome: Ongoing pregnancy rate

Eligibility

Minimum age: 18 Years. Maximum age: 43 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- all patients 43 years old or under undergoing fresh or frozen IVF cycles are eligible

to participate Exclusion Criteria:

- patients greater than 43 years old

- patinets currently participating in any other research studies

Locations and Contacts

Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey 07960, United States

Reproductive Medicine Associates of Pennsylvania at Lehigh Valley, Allentown, Pennsylvania 18104, United States

Additional Information

Reproductive Medicine Associates of New Jersey

Starting date: May 2012
Last updated: January 21, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017